Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Keywords

MedicineRefractory (planetary science)OncologyLymphomaInternal medicineMaterials science

Affiliated Institutions

Related Publications

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

Shannon L. Maude , Theodore W. Laetsch , Jochen Buechner +32 more

In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients wit...

2018 New England Journal of Medicine 5232 citations

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster , Michael Bishop , Constantine S. Tam +21 more

In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use o...

2018 New England Journal of Medicine 3775 citations

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Rita Nanda , Laura Q.M. Chow , Elizabeth Claire Dees +9 more

Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negativ...

2016 Journal of Clinical Oncology 1427 citations

Isolation of a candidate human hematopoietic stem-cell population.

C Baum , I L Weissman , Atsushi Tsukamoto +2 more

We have identified a rare (0.05-0.1%) subset of human fetal bone marrow cells that contains multipotent hematopoietic precursors. The population of human precursor cells that ex...

1992 Proceedings of the National Academy o... 1079 citations

Cancer immunotherapy using checkpoint blockade

Antoni Ribas , Jedd D. Wolchok

The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses i...

2018 Science 6236 citations

Publication Info

Year: 2018
Type: article
Volume: 20
Issue: 1
Pages: 31-42
Citations: 2108
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2108

OpenAlex

Cite This

APA Style

                            
                                
                                    Frederick L. Locke, 
                                
                                    Armin Ghobadi, 
                                
                                    Caron A. Jacobson
                                
                                et al.
                            
                            (2018). 
                            Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. 
                            The Lancet Oncology
                            , 20
                            (1)
                            , 31-42.
                            https://doi.org/10.1016/s1470-2045(18)30864-7
                        

Identifiers

DOI: 10.1016/s1470-2045(18)30864-7